These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
129 related items for PubMed ID: 20003831
1. DD3(PCA3) gene expression in cancer and prostatic hyperplasia. Floriano-Sánchez E, Cárdenas-Rodríguez N, Castro-Marín M, Alvarez-Grave P, Lara-Padilla E. Clin Invest Med; 2009 Dec 01; 32(6):E258. PubMed ID: 20003831 [Abstract] [Full Text] [Related]
2. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis. Klecka J, Holubec L, Pesta M, Topolcan O, Hora M, Eret V, Finek J, Chottova-Dvorakova M, Babjuk M, Novak K, Stolz J. Anticancer Res; 2010 Feb 01; 30(2):665-70. PubMed ID: 20332487 [Abstract] [Full Text] [Related]
3. [Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction]. Tao ZH, Mao XL, Wang CH, Chen XD, Yu KY, Weng ZL, Hu YP, Zhang XH, Xie H, Wang OC, Song QT, Li CD, Chen ZG. Zhonghua Nan Ke Xue; 2007 Feb 01; 13(2):130-3. PubMed ID: 17345768 [Abstract] [Full Text] [Related]
4. [Detection of urine DD3/PSA mRNA ratio by duplex TaqMan RT-PCR assay and evolution of its primary application]. Chen FP, Chen LL, Shen M, Chen W, Tao ZH, Wu XL, Hu YP, Li CD, Chen ZG, Chen XD. Zhonghua Yi Xue Za Zhi; 2008 Jan 22; 88(4):261-4. PubMed ID: 18361839 [Abstract] [Full Text] [Related]
5. Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue. Bialkowska-Hobrzanska H, Driman DK, Fletcher R, Harry V, Razvi H. Can J Urol; 2006 Feb 22; 13(1):2967-74. PubMed ID: 16515751 [Abstract] [Full Text] [Related]
6. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. Cancer Res; 2002 May 01; 62(9):2695-8. PubMed ID: 11980670 [Abstract] [Full Text] [Related]
7. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Neves AF, Araújo TG, Biase WK, Meola J, Alcântara TM, Freitas DG, Goulart LR. Clin Biochem; 2008 Oct 01; 41(14-15):1191-8. PubMed ID: 18640109 [Abstract] [Full Text] [Related]
8. [Quantitative detection of differential display code 3 mRNA in peripheral blood of patients with prostate cancer]. Weng ZL, Yu KY, Mao XL, Tao ZH, Chen XD, Wu XL, Hu YP, Wang SQ, Li CD, Chen ZG. Zhonghua Yi Xue Za Zhi; 2006 Nov 07; 86(41):2911-5. PubMed ID: 17288789 [Abstract] [Full Text] [Related]
9. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer. Mearini E, Antognelli C, Del Buono C, Cochetti G, Giannantoni A, Nardelli E, Talesa VN. Biomarkers; 2009 Jun 07; 14(4):235-43. PubMed ID: 19489685 [Abstract] [Full Text] [Related]
10. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Robert G, Jannink S, Smit F, Aalders T, Hessels D, Cremers R, Mulders PF, Schalken JA. Prostate; 2013 Jan 07; 73(2):113-20. PubMed ID: 22674214 [Abstract] [Full Text] [Related]
11. Is DD3 a new prostate-specific gene? Gandini O, Luci L, Stigliano A, Lucera R, Di Silverio F, Toscano V, Cardillo MR. Anticancer Res; 2003 Jan 07; 23(1A):305-8. PubMed ID: 12680228 [Abstract] [Full Text] [Related]
12. [Detection of DD3 mRNA in the urine of prostate cancer patients and its clinical significance]. Liu GX, Guo HQ, Li XG, Gan WD, Zeng LQ, Shi HL, Zhang SW, Liu TS. Zhonghua Nan Ke Xue; 2007 Jun 07; 13(6):511-3. PubMed ID: 17615974 [Abstract] [Full Text] [Related]
13. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions. Schostak M, Miller K, Krause H, Schrader M, Kempkensteffen C, Kollermann J. Cancer Detect Prev; 2006 Jun 07; 30(5):449-54. PubMed ID: 17067752 [Abstract] [Full Text] [Related]
14. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. Cancer Res; 1999 Dec 01; 59(23):5975-9. PubMed ID: 10606244 [Abstract] [Full Text] [Related]
15. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms. Brys M, Stawinska M, Foksinski M, Barecki A, Zydek C, Miekos E, Krajewska WM. Oncol Rep; 2004 Jan 01; 11(1):219-24. PubMed ID: 14654929 [Abstract] [Full Text] [Related]
16. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Tilli TM, Thuler LC, Matos AR, Coutinho-Camillo CM, Soares FA, da Silva EA, Neves AF, Goulart LR, Gimba ER. Exp Mol Pathol; 2012 Feb 01; 92(1):13-9. PubMed ID: 21963599 [Abstract] [Full Text] [Related]
17. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study. van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA. Prostate; 2009 Nov 01; 69(15):1624-34. PubMed ID: 19588525 [Abstract] [Full Text] [Related]
18. Quantitative real-time RT-PCR assay for PCA3. Väänänen RM, Rissanen M, Kauko O, Junnila S, Väisänen V, Nurmi J, Alanen K, Nurmi M, Pettersson K. Clin Biochem; 2008 Jan 01; 41(1-2):103-8. PubMed ID: 17996198 [Abstract] [Full Text] [Related]
19. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Schalken JA, Hessels D, Verhaegh G. Urology; 2003 Nov 01; 62(5 Suppl 1):34-43. PubMed ID: 14607216 [Abstract] [Full Text] [Related]
20. [Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance]. Liu BQ, Wu YD, Wei JX, Zhang T, Liu RL, Ma TX. Zhonghua Nan Ke Xue; 2007 Nov 01; 13(11):997-1001. PubMed ID: 18077911 [Abstract] [Full Text] [Related] Page: [Next] [New Search]